Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer

Journal of Gastrointestinal Surgery

Volumn 6, Issue 6, 2002, Pages 838-844

  Tseng, William W ^a,b   Deganutti, Adriana ^b   Chen, May N ^b   Saxton, Romaine E ^b   Liu, Carson D ^b   Chandler, G ^c   Jaffe, M ^c   Brentnall, T ^c   Billingsley, K G ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE

Author keywords

Cell cycle; Cyclooxygenase 2; Microarray; Pancreas cancer; Rofecoxib

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; ROFECOXIB; CYCLIN D1; LACTONE; PROSTAGLANDIN SYNTHASE INHIBITOR; SULFONE;

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE; CELL GROWTH; CONTROLLED STUDY; DNA MICROARRAY; GENE OVEREXPRESSION; GROWTH DISORDER; HUMAN; HUMAN CELL; HUMAN VERSUS ANIMAL COMPARISON; LAPAROTOMY; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; RNA ISOLATION; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; COMPARATIVE STUDY; DISEASE COURSE; DISEASE MODEL; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; PANCREAS; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROBABILITY; RANDOMIZATION; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL CYCLE; CYCLIN D1; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LACTONES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PANCREAS; PANCREATIC NEOPLASMS; PROBABILITY; RANDOM ALLOCATION; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SULFONES; TUMOR CELLS, CULTURED;

EID: 15944388899     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1091-255X(02)00061-6     Document Type: Article

References (22)

1. DiMagno EP, Reber HA, Tempero MA. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology 1999;11: 1464-1484.
2. Greenlee RT, Murray T, Bolden S, et al. Cancer Statistics 2000. CA Cancer J Clin 2000;50:7-33.
3. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-442.
4. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 2000;37:431-502.
5. Kokawa A, Kondo H, Gotoda T, et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 2001;91:333-338.
6. Koshiba T, Hosotani R, Miyamoto Y, et al. Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors. Int J Pancreatol 1999;26:69-76.
7. Merati K, said Siadaty M, Andea A, et al. Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters. Am J Clin Oncol 2001;24:447-452.
8. Molina MA, Sitja-Arnau M, Lemoine MG, et al. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999;59:4356-4362.
9. Okami J, Yamamoto H, Fujiwara Y, et al. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res 1999;5:2018-2024.
10. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is upregulated in human pancreatic cancer. Cancer Res 1999;59:987-990.
11. Yip-Schneider MT, Barnard DS, Billings SD, et al. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 2000;21:139-146.
12. Ding XZ, Tong WG, Adrian TE. Blockage of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res 2000;20:2625-2632.
13. Liu CD, Deganutti A, Saxton RE. Cyclooxygenase-2 (COX-2) inhibition decreases human pancreatic cancer cell growth and angiogenesis. Surg Forum 2001;52:211-212.
14. Yip-Schneider MT, Sweeny CJ, Jung SH, et al. Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther 2001; 298:976-985.
15. Liu CD, Slice LW, Balasubramaniam A, et al. Y2 receptors decrease human pancreatic cancer growth and intracellular cyclic adenosine monophosphate levels. Surgery 1995;118: 229-235.
16. Oshima M, Murai N, Kargman S, et al. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001; 61:1733-1740.
17. Takahashi M, Furukawa F, Toyoda K, et al. Effects of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after initiation with N-nitrosobis (2-oxopropyl)amine. Carcinogenesis 1990;11:393-395.
18. Perugini RA, McDade TP, Vittimberga FJ Jr, Callery MP. The molecular and cellular biology of pancreatic cancer. Crit Rev Eukaryot Gene Exp 1998;8:377-393.
19. Gansauge S, Gansauge F, Ramadani M, et al. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res 1997;57:1634-1637.
20. Cheung KJ Jr, Li G. The tumor suppressor ING1: Structure and function. Exp Cell Res 2001;268:1-6.
21. Amundson SA, Zhan Q, Penn LZ, Fornace AJ Jr. Myc suppresses induction of the growth arrest genes GADD34, GADD45, and GADD153 by DNA-damaging agents. Oncogene 1998;17:2149-2154.
22. Dicker AP, Williams TL, Grant DS. Targeting angiogenic processes by combination rofecoxib and ionizing radiation. Am J Clin Oncol 2001;24:438-442.